We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Celgene Corporation | NASDAQ:CELG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 108.24 | 109.30 | 109.44 | 0 | 01:00:00 |
Celgene Corp. announced on Monday that it will present data on its Crohn's disease drug GED-0301 at a conference Tuesday. The company posted an abstract with top-line results on the high side of expectations.
Phase-2 trial of Crohn's disease drug Mongersen came in on the high side of expectations. Remission rates of 55% in the 40 mg group and 65% in the 160 mg group were compared to 9.5% in the placebo group.
The drug could be a blockbuster for the biotech company.
PennyStockTitans wants to help everyday people gain awareness about some of the hottest stocks trading in the stock market today. PennyStockTitans.com releases momentum alerts on companies that you may have never heard about or thought about looking at. Take a few minutes to register with us at http://www.pennystocktitans.com/ to get full access to our free stock reports.
A shareholder of Fannie Mae and Freddie Mac (FMCC) is suing the government and has filed a brief in federal court in Iowa. The shareholder is arguing that a federal judge in Washington, D.C. reached the wrong decision when he dismissed a similar case last month.
The filing marks the first time lawyers for plaintiffs in various Fannie and Freddie lawsuits have responded in detail to Judge Royce C. Lamberth’s decision.
It argues that Judge Lamberth made an error by allowing the Federal Housing Finance Agency more discretion in its role as a conservator than the law allows. It asks the Iowa court to give the Lamberth decision “no weight.”
Fannie and Freddie shares sank after the Lamberth decision
Disclosure: PennyStockTitans.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.
1 Year Celgene Chart |
1 Month Celgene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions